The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study

Casper Rokx; M Blonk; Annelies Verbon; D Burger; Bart Rijnders

doi:10.7448/IAS.17.4.19789

The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study

Casper Rokx
, M Blonk
, Annelies Verbon
, D Burger
, Bart Rijnders

Internal Medicine

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	181-182
Number of pages	2
Journal	Journal of the International AIDS Society
Volume	17
DOIs	https://doi.org/10.7448/IAS.17.4.19789
Publication status	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Research programs

EMC MM-04-28-04

Access to Document

10.7448/IAS.17.4.19789

Cite this

@article{422fe16a9718466f922dc4455dd86bad,

title = "The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study",

author = "Casper Rokx and M Blonk and Annelies Verbon and D Burger and Bart Rijnders",

year = "2014",

doi = "10.7448/IAS.17.4.19789",

language = "Undefined/Unknown",

volume = "17",

pages = "181--182",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "John Wiley \& Sons Inc.",

}

TY - JOUR

T1 - The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch study

AU - Rokx, Casper

AU - Blonk, M

AU - Verbon, Annelies

AU - Burger, D

AU - Rijnders, Bart

PY - 2014

Y1 - 2014

U2 - 10.7448/IAS.17.4.19789

DO - 10.7448/IAS.17.4.19789

M3 - Article

C2 - 25397533

SN - 1758-2652

VL - 17

SP - 181

EP - 182

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

ER -